Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback